{
  "retracted": false,
  "timestamp": 1403136000000,
  "updates": [
    {
      "timestamp": 1574728337540,
      "identifier": {
        "doi": "10.1007/s10549-014-3010-y"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s10549-014-2923-9"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer"
}
